Monoclonal antibody (mAb) therapy is a type of cancer immunotherapy. It is now being used increasingly to treat cancer now a day. After recognizing the antigen against which the antibody is directed, they get fitted together similarly as a two pieces of a puzzle setting off a cascade of events resulting in tumor cell death.

GAP possesses an innovative biopharmaceutical platform with the capability to propel this company in development of the immunotherapeutic cancer agents.

Despite the fact that monoclonal antibodies are a type of immunotherapy, it is also a type of targeted treatment. It has multiple roles in cancer therapy and can be used directly as therapy.TheUS Food and Drug Administration (FDA) have approved more than a dozen of mAbs to treat various cancers. Currently, newer mAbs are now being done on many types of cancer.Various types of monoclonal antibodies are used in cancer treatments. It includes naked monoclonal antibodies, Conjugated monoclonal antibodies and bispecific monoclonal antibodies.

Naked mAbs act by themselves and get attached to antigens on cancer cells.But few of them work by binding to antigens on other non-cancerous cells. Naked mAbs can work in different ways which includes enhancement ofa person’s immune response against cancer cells by attaching to them and acting as a marker for the body’s immune system to destroy them like Alemtuzumab (it is used to treat chronic lymphocytic leukemia). Some of them increase immune response by targeting immune system checkpoints.While others work mainly by attaching to and blocking antigens that are important signals for cancer cells like Trastuzumab (used in breast and stomach cancer).

Conjugated monoclonal antibodies are mAbs which joined to a chemotherapy drug, toxin or a radioactive particle.An example of a radiolabeled mAb is Ibritumomab tiuxetan. Chemolabeled antibodies which are approved by the FDA are Brentuximab vedotin (it is used to treat Hodgkin lymphoma and anaplastic large cell lymphoma) and Ado-Trastuzumab emtansine (it is used in advanced breast cancer).

Bispecific monoclonal antibodies are drugs which are made up of two different parts of mAbs, by getting attached to two different proteins at the same time. An example is blinatumomab, which is used to treat some types of acute lymphocytic leukemia. One part of it binds to the CD19 protein, while other part get bind to CD3. Due to this, the drug brings the cancer cells and immune cells simultaneously which is thought to cause the immune system to attack the cancer cells.

Although being the most widely used form of cancer immunotherapy, more advancement is still needed for monoclonal antibodies to become successful as expected.Global Allied Pharmaceutical’s medical oncologists are being active and dynamic in the clinical trials associated with various novel therapies. These therapeutic agents include state-of-the-art drugs and different immunological and new biological modifiers at the investigational level.

Contact us: 160 Vista Oak Dr.

Longwood, FL 32779

Telephone: 321-445-1969